313355-01-0

Basic information

• Product Name: (2R,3R,4R)-1-Azido-3,4-bis-benzyloxy-4-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-2-ol
• Synonyms: (2R,3R,4R)-1-Azido-3,4-bis-benzyloxy-4-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-2-ol
• CAS NO: 313355-01-0
• Molecular Weight: 427.5
• Mol File: 313355-01-0.mol

Chemical Properties

• CAS DataBase Reference: (2R,3R,4R)-1-Azido-3,4-bis-benzyloxy-4-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R,4R)-1-Azido-3,4-bis-benzyloxy-4-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-2-ol(313355-01-0)
• EPA Substance Registry System: (2R,3R,4R)-1-Azido-3,4-bis-benzyloxy-4-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-butan-2-ol(313355-01-0)

Safety Data

• Hazardous Substances Data: 313355-01-0(Hazardous Substances Data)

Upstream product

• 111476-62-1 3,4-di-O-benzyl-1,2:5,6-di-O-isopropylidene-D-mannitol 
• 152310-26-4 3,4-di-O-benzyl-1,2-O-isopropylidene-6-O-p-toluenesulfonyl-D-mannitol 
• 121964-05-4 3,4-di-O-benzyloxy-5,6-O-isopropylidene-D-mannitol 

Downstream Products

• 313355-03-2 N-Boc-6-amino-2,5-anhydro-3,4-di-O-benzyl-6-deoxy-D-mannitol 
• 840540-56-9 N-Boc-6-amino-2,5-anhydro-3,4-di-O-benzyl-6-deoxy-D-mannonic acid 
• 219631-58-0 methyl N-Boc-6-amino-2,5-anhydro-3,4-di-O-benzyl-6-deoxy-D-mannonate 
• 155696-77-8 6-azido-3,4-di-O-benzyl-6-deoxy-D-mannitol 
• 313355-02-1 (S)-2-[(1R,2S)-1,2-Bis-benzyloxy-2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-ethyl]-aziridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis and conformational studies of 3,4-di-O-acylated furanoid sugar amino acid-containing analogs of the receptor binding inhibitor of vasoactive intestinal peptide

Structural analysis of the di-O-caprylated Gaa-containing analog of the receptor binding inhibitors of vasoactive intestinal peptide by various NMR techniques and constrained molecular dynamics (MD) simulation studies established a well-defined β-turn str

Novel peptides comprising furanoid sugar amino acids for the treatment of cancer

Anticancer peptides which incorporate furanoid sugar amino acids and compositions made using these peptides are described. Methods for synthesis of the peptides and for preparing the furanoid sugar amino acids are disclosed. The peptides and compositions made using the peptides have pharmacological applications of these peptides especially in the treatment and prevention of cancer and tumors.

Synthesis and structural studies of oligomers of 6-amino-2,5-anhydro-6-deoxy-D-mannonic acid

A novel cycloetherification process involving a facile 5-exo S(N)2-type ring closure by intramolecular opening of a terminal aziridine ring by a γ-hydroxyl group, led to the stereoselective synthesis of 6-amino-2,5-anhydro-6-deoxy-D-mannonic acid (1). Oligomerization of 1 by solution phase peptide coupling methods gave oligomers 2-5. While most of the oligomers, in either protected or deprotected form, did not show any significant secondary structure, octamer 5 (P = H) exhibited a very strong positive band at 216 nm in its CD spectrum in MeOH and TFE, indicating the possibility of the presence of an ordered structure in solution. Its 1H NMR spectra in various polar solvents, however, failed to produce any distinct dispersion of the amide proton chemical shifts. Compounds 1-5 were found to be inactive in hypoglyceamic tests in rats. (C) 2000 Elsevier Science Ltd.